Composition for ameliorating, preventing or treating osteoarthritis comprising bifidobacterium bifidum BGN4

By using bifidobacterium bifidum BGN4 food or pharmaceutical composition, the side effects and frequency of surgical problems of non-steroidal anti-inflammatory drugs in osteoarthritis treatment are solved, which significantly relieves pain and inflammation, protects joint tissues, and provides A safe and continuous prevention and treatment program is provided.

CN118985702APending Publication Date: 2024-11-22BIFIDO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410213281.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2024-02-27
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Among the existing treatment methods for osteoarthritis, the long-term use of non-steroidal anti-inflammatory drugs leads to gastrointestinal side effects, and elderly patients require frequent surgery and drug treatment, and lack effective prevention and treatment methods.

Method used

Using a food or pharmaceutical composition containing bifidobacterium bifidum BGN4, through its culture medium or dry powder, as a method for improving, preventing or treating osteoarthritis, to relieve pain, control inflammation and prevent cartilage damage. .

Benefits of technology

Through experimental verification, Bifidobacter bifidobacterium BGN4 significantly alleviates pain caused by osteoarthritis, reduces the expression of biomarkers related to inflammation and cartilage destruction, protects joint tissue, and provides a safe and continuous treatment and prevention of osteoarthritis. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118985702A_ABST
    Figure CN118985702A_ABST
Patent Text Reader

Abstract

The present invention relates to a composition for ameliorating, preventing or treating osteoarthritis, said composition comprising bifidobacterium bifidum BGN4, said composition being characterized by comprising bifidobacterium bifidum BGN4 (preservation number: KCCM12754P), and to a method for improving, preventing or treating osteoarthritis, said composition comprising bifidobacterium bifidum BGN4 (preservation number: KCCM12754P). According to the application of the bifidobacterium bifidum BGN4 disclosed by the invention, an osteoarthritis mouse model experiment confirms that the bifidobacterium bifidum BGN4 relieves the pain caused by the osteoarthritis and has a control effect on the damage of joint tissues caused by the osteoarthritis. In addition, it has been confirmed in the treated group of strains of the present invention that the expression amounts of IL-1beta, IL-6, and LTB4R, which are inflammation-related biomarkers that cause osteoarthritis, MMP9, MMP13, and CTX-II, which are cartilage destruction-related biomarkers, and PGE2, which are inflammation-related and cartilage destruction-related biomarkers, are small.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a composition for improving, preventing or treating osteoarthritis, characterized in that it contains Bifidobacterium bifidum BGN4 (deposit number: KCCM12754P). Background Art

[0002] Osteoarthritis is a disease caused by degenerative changes in articular cartilage present between joints, and it is known that physical loads caused by weight changes or inflammatory factors caused by cartilage damage have a great influence on the development of the disease. Regarding the prevalence of osteoarthritis, the prevalence of degenerative arthritis in the elderly population over 65 years old is about 37.8%, the prevalence of men is 20.2%, and the prevalence of women is 50.1%, showing that the prevalence of women is about 3 times higher than that of men.

[0003] In the treatment of early osteoarthritis, the most commonly prescribed drugs for relieving pain and controlling inflammation are nonsteroidal anti-inflammatory drugs (NSAIDs). Other treatments for osteoarthritis include intra-articular steroid injections and prescriptions for disease modifying anti-osteoarthritis drugs (DMOADs). However, long-term NSAID treatment can cause a variety of gastrointestinal side effects ranging from mild indigestion to ulcers, bleeding, and perforation.

[0004] On the other hand, elderly patients with osteoarthritis require artificial joint replacement surgery due to the severity of cartilage damage, and need to undergo another surgery approximately every 10 years. If the inflammation at the surgical site worsens, there is a disadvantage of needing to take additional anti-inflammatory drugs and other medications.

[0005] Prior art literature

[0006] Patent Literature

[0007] Patent Document 1: Korean Patent Publication No. 10-2022-0095021 (2022.07.06) describes a composition for improving, preventing or treating bone diseases containing a Lactobacillus curvatus strain.

[0008] Patent document 2: Korean Patent No. 10-2007144 (2019.07.29) describes a Lactobacillus plantarum strain that has the effect of improving osteoarthritis or rheumatoid arthritis. Summary of the invention

[0009] The present invention aims to provide a composition that can improve, prevent or treat osteoarthritis.

[0010] The present invention provides a food composition for improving osteoarthritis, characterized in that it comprises Bifidobacterium bifidum BGN4 (preservation number: KCCM12754P), its culture solution or dry powder of its culture solution.

[0011] Preferably, the food composition is any one selected from lactic acid bacteria fermented milk, soy milk, milk powder, yogurt, beverages, granules or health supplementary foods.

[0012] Furthermore, the present invention provides a pharmaceutical composition for preventing or treating osteoarthritis, characterized in that it comprises Bifidobacterium bifidum BGN4 (Deposit No.: KCCM12754P), a culture solution thereof, or a dry powder of the culture solution.

[0013] The present invention provides a composition for improving, preventing or treating osteoarthritis, comprising Bifidobacterium bifidum BGN4 (KCCM12754P). BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 This is a graph showing the results of measuring the pain threshold (paw withdrawal threshold) through an osteoarthritis animal model experiment in order to confirm whether the strain of the present invention has an effect of improving pain caused by osteoarthritis.

[0015] Figure 2 The present invention is a graph showing the results of measuring the weight bearing (weight on right hind limb) of the leg with osteoarthritis in an osteoarthritis animal model experiment in order to confirm whether the strain of the present invention has an effect of improving pain caused by osteoarthritis.

[0016] Figure 3 This is a graph showing the results of measuring the concentrations of type II collagen C-terminal peptide (CTX-II) and interleukin 6 (IL-6) in serum collected after an osteoarthritis animal model experiment in order to confirm whether the strain of the present invention has the effect of preventing cartilage damage caused by osteoarthritis. On the other hand, collagen C-terminal peptide (CTX) is a biomarker associated with cartilage destruction, and IL-6 is a biomarker associated with inflammation.

[0017] Figure 4 In order to confirm whether the strain of the present invention has an effect of preventing knee joint damage caused by osteoarthritis, micro-CT (micro-CT) images of knee joint tissue were taken and observed.

[0018] Figure 5 To show the above numerically Figure 4 The result curve graph of bone volume and bone surface.

[0019] Figure 6 In order to confirm whether the strain of the present invention has an effect of preventing knee joint damage caused by osteoarthritis, knee joint tissue was stained with Safranin O and observed.

[0020] Figure 7 To show the Mankin score and the Osteoarthritis Research Society International (OARSI) evaluation criteria for the above Figure 6 The curve graph shows the results of scoring the degree of damage to the knee joint tissue.

[0021] Figures 8 to 12 This image was obtained by performing immunohistochemistry (IHC) analysis on knee joint tissue in order to confirm the expression levels of biomarkers that cause osteoarthritis (interleukin 1β (IL-1β), prostaglandin E2 (PGE2), matrix metalloproteinase 9 (MMP9), matrix metalloproteinase 13 (MMP13), and leukotriene B4 receptor (LTB4R)) in knee joint tissue.

[0022] Fig.13 To show the above numerically Figures 8 to 12 The result graphs of the expression levels of the biomarkers are shown in FIG. DETAILED DESCRIPTION

[0023] The present invention provides a food composition for improving osteoarthritis, characterized in that it comprises Bifidobacterium bifidum BGN4 (preservation number: KCCM12754P), its culture solution or dry powder of its culture solution.

[0024] In the following examples, it can be confirmed by osteoarthritis model mouse experiments that the strain of the present invention has excellent efficacy in improving, preventing or treating osteoarthritis. Specifically, in the following examples, it can be confirmed that the strain of the present invention relieves the pain caused by osteoarthritis and has a control effect on the destruction of joint tissue caused by osteoarthritis. In addition, it can be confirmed in the strain treatment group of the present invention that the expression of IL-1β, IL-6, LTB4R, MMP9, MMP13, CTX-Ⅱ, and PGE2, which are biomarkers related to inflammation and cartilage destruction, which cause osteoarthritis, is low.

[0025] On the other hand, the Bifidobacterium bifidum BGN4 (Deposit Number: KCCM12754P) of the present invention is a strain deposited in the Korea Collection of Microorganisms (overseas) on June 24, 2020, with a deposit number of KCCM12754P. In addition, it is a strain disclosed by Korean Patent No. 10-2362828 (authorized on February 9, 2022) and the like.

[0026] On the other hand, in the present invention, the example of food composition can be any one selected from meat, cereals, caffeine beverages, ordinary beverages, chocolate, bread, snacks, biscuits, candy, pizza, soft candy, noodles, chewing gum, dairy products, ice cream, alcoholic beverages, wine, multivitamins and other health supplements. More preferably, it can be any one selected from lactobacillus fermented milk, soy milk, milk powder, yogurt, beverages, granules or health supplements, but is not limited thereto.

[0027] Furthermore, the present invention provides a pharmaceutical composition for preventing or treating osteoarthritis, characterized in that it comprises Bifidobacterium bifidum BGN4 (Deposit No.: KCCM12754P), a culture solution thereof, or a dry powder of the culture solution.

[0028] On the other hand, the pharmaceutical composition of the present invention can also include pharmaceutically acceptable carriers, diluents or excipients. Operable carriers, excipients or diluents include lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talcum powder, magnesium stearate and mineral oil, and more than one selected from them can be used. And, when therapeutic agent and preventive agent are medicaments, fillers, anticoagulants, lubricants, wetting agents, spices, emulsifiers or preservatives etc. can be further included.

[0029] On the other hand, the dosage form of the pharmaceutical composition of the present invention can be prepared into the best form according to the method of use, in particular, it is preferably formulated by using methods known in the art so that the active ingredient is provided for rapid, sustained or delayed release after administration to a mammal. Specific examples of dosage forms can be selected from plasters, granules, lotions, liniments, lemonades, aromatic waters, powders, syrups, ophthalmic ointments, liquids and solutions, aerosols, extracts, elixirs, ointments, fluid extracts, emulsions, suspensions, decoctions, infusions, eye drops, and ointments. Any of solutions, tablets, suppositories, injections, spirits, granules, capsules, creams, troches, tinctures, pastes, pills, soft or hard gelatin capsules.

[0030] On the other hand, in the pharmaceutical composition of the present invention, the dosage is preferably determined in consideration of the method of administration, the age, sex, weight of the user, and the severity of the disease. For example, based on the active ingredient, it can be orally administered once or more per day in an amount of 0.00001 mg / kg (body weight) to 100 mg / kg (body weight). However, the above dosage is only an example for illustration and can be changed by the prescribing of the probiotic according to the state of the user.

[0031] Hereinafter, the content of the present invention will be described in more detail by the following examples. However, the scope of the invention claimed in the present invention is not limited to the following examples, but also includes the deformation of the technical concept equivalent thereto.

[0032] Example 1: Experiment to confirm the efficacy of the strain of the present invention in improving, preventing or treating osteoarthritis

[0033] (1) Experimental purpose

[0034] The aim was to confirm whether five strains (Bifidobacterium bifidum ATT, Bifidobacterium longum BORI, Bifidobacterium longum RAPO, Bifidum bifidum BGN4, and Lactobacillus sakei RH1117) showed excellent efficacy against osteoarthritis.

[0035] To this end, in this example, the osteoarthritis animal model was treated with the above-mentioned strains, and pain threshold measurement, weight-bearing measurement, serum analysis, micro-CT measurement, and tissue analysis were used to comprehensively evaluate whether the strains exhibited excellent efficacy on osteoarthritis.

[0036] On the other hand, all data were expressed as mean ± SEM, and statistical significance was verified by two-way ANOVA (Bonferroni posttests), Kruskal-Wallis test (Dunn's posttests), and Mann-Whitney test using GraphPadPRISM Version 5.0 (GraphPad Software, USA) analysis program. The data were considered significant when P < 0.05.

[0037] (2) Experimental methods of osteoarthritis animal model

[0038] The osteoarthritis animal model used in the present embodiment is a model in which osteoarthritis is induced by injecting sodium iodoacetate (MIA) into the joint cavity of rats. MIA inhibits the synthesis of proteoglycans in cartilage by activating matrix metalloproteinases (MMP) to cause necrosis of chondrocytes, thereby causing symptoms similar to osteoarthritis. The osteoarthritis animal model using MIA is a chemical model representing elderly patients with advanced osteoarthritis and is a model suitable for screening therapeutic agents that control pain while protecting cartilage.

[0039] The specific osteoarthritis model experimental method is as follows. A strain suspension (6×10 9 CFU / tube). On the day of the experiment, sodium iodoacetate (Sigma, Cat. No. I2512) was dissolved in saline for injection to prepare a concentration of 60 mg / mL, and 50 μL of the prepared solution was administered to the knee joint of WISTAR rats to induce osteoarthritis. After inducing osteoarthritis in rats, 1 mL of the prepared strain suspension was orally administered once a day for a total of 14 times starting 3 days later for 2 weeks.

[0040] On the other hand, the experiment was conducted using normal saline as a negative control group and Celecoxib, which is used to treat osteoarthritis, as a positive control group.

[0041] (3) Pain threshold measurement experiment

[0042] When you have osteoarthritis, your pain threshold is lowered, which can lead to more severe pain.

[0043] In this example, the purpose is to confirm whether the pain threshold lowered due to osteoarthritis is improved by treating with the strain of the present invention by measuring the pain threshold in the above-mentioned osteoarthritis animal model experiment.

[0044] The pain threshold was measured using a dynamic plantar aesthesiometer (UgoBasile, 37400, Comerio, Italy), which was measured by slowly increasing the force applied to the animal's foot within a specified time. The animal was placed in an acrylic box with a wire mesh bench at the bottom for 5 minutes to adapt and then measured to reduce the error before measurement. On the other hand, for the pain threshold, a metal filament was used to gradually apply a force from 0 g to 50 g to the center of the bottom of the right hind paw of each animal within 10 seconds to measure the weight of the animal's paw retraction reaction (paw retraction threshold (g)) ( Figure 1 ).

[0045] from Figure 1It was confirmed that the pain threshold of the group treated with Bifidum bifidum BGN4 was improved. The above results indicate that Bifidum bifidum BGN4 has an excellent effect on improving pain caused by osteoarthritis.

[0046] (4) Weight measurement experiment

[0047] When you have osteoarthritis, the other leg may bear more of the load due to the pain.

[0048] In this example, the purpose is to confirm whether the pain caused by osteoarthritis is alleviated by treating with the strain of the present invention by measuring the weight-bearing in the above-mentioned osteoarthritis animal model experiment.

[0049] The weight-bearing measurement is an experiment to measure the change in weight-bearing (or weight distribution) between the normal hind leg (left side) and the hind leg with arthritis (right side) caused by the pain in the unilateral arthritic knee of the hind leg. The weight-bearing of the hind paws on both sides is measured respectively using an incapacitance tester (Model 600, IITC, USA) as a device for measuring weight-bearing. The animals are placed in an acrylic box for 5 minutes of adaptation before being measured to reduce errors. The measurement is performed when each animal is accurately positioned on the measuring device, but the measurement time is measured twice at intervals of 5 seconds, and the average value is used as the weight-bearing (g) value of each paw. The experimental results are expressed as the ratio of the weight-bearing of the right leg with arthritis to the weight-bearing of the legs on both sides (the weight on the right hind leg (%)) ( Figure 2 ).

[0050] from Figure 2 It was confirmed that the weight-bearing imbalance was improved in the group treated with Bifidobacterium bifidum BGN4. The above results indicate that Bifidum bifidum BGN4 has an excellent effect on improving pain caused by osteoarthritis.

[0051] (5) Serum CTX-Ⅱ, IL-1β, and IL-6 concentration analysis experiment

[0052] IL-1β and IL-6 are inflammatory mediators, and it is known that the expression levels of IL-1β and IL-6 in osteoarthritis increase with the occurrence of inflammation. CTX-Ⅱ is one of the type II collagens that is degraded by matrix metalloproteinases (MMPs), one of the enzymes that degrade cartilage, and it is known that the concentration of CTX-Ⅱ in osteoarthritis increases with the destruction of articular cartilage due to inflammation.

[0053] In this example, the concentrations of CTX-II, IL-1β, and IL-6 in the serum of the above-mentioned osteoarthritis animal model were determined to confirm whether treatment with the strain of the present invention can prevent cartilage damage caused by osteoarthritis.

[0054] To this end, after the osteoarthritis animal model experiment was completed, serum was obtained from the blood of the experimental group, and the concentrations of CTX-Ⅱ and IL-6 in the serum were measured using an analytical kit ( Figure 3 ).

[0055] from Figure 3 It was confirmed that the expression of CTX-II and IL-6 decreased in the B. bifidum BGN4-treated group. The above results indicate that B. bifidum BGN4 has an excellent effect on preventing cartilage damage caused by osteoarthritis.

[0056] (6) Joint tissue analysis

[0057] In this example, the purpose is to confirm whether the treatment with the strain has the effect of protecting the joints by observing the joint tissues obtained after the above-mentioned osteoarthritis animal model experiment.

[0058] To this end, after the osteoarthritis animal model experiment, the extent of bone destruction was confirmed by fixing the knee joint tissue in formalin and taking micro-CT scans ( Figure 4 Then, based on the above results, the bone volume and bone surface are expressed numerically ( Figure 5 ).

[0059] from Figure 5 It was confirmed that the bone volume and bone surface were higher in the B. bifidum BGN4 treated group than in the positive control group (50 mg / kg of celecoxib). The above results indicate that B. bifidum BGN4 has an excellent effect on preventing joint damage caused by osteoarthritis.

[0060] In addition, knee joint tissues were stained with safranin O ( Figure 6 ), and the degree of damage to the knee joint tissue was evaluated according to the Mankin total score and OARSI evaluation criteria ( Figure 7 ).

[0061] from Figure 7 It was confirmed that the Mankin total score and OARSI score were lower in the group treated with Bifidobacterium bifidum (B. bifidum) BGN4. These results indicate that Bifidum bifidum (B. bifidum) BGN4 has an excellent effect on preventing joint damage caused by osteoarthritis.

[0062] (7) Immunohistochemical analysis

[0063] In this example, the expression pattern of osteoarthritis-related biomarkers treated with the strains was confirmed by immunohistochemical analysis of the joint tissues obtained after the above-mentioned osteoarthritis animal model experiment.

[0064] To this end, the knee joint tissues were fixed in formalin and made into paraffin blocks after a decalcification process. The obtained sections were subjected to immunohistochemical analysis to confirm the expression levels of IL-1β, PGE2, MMP9, MMP13, and LTB4R in the knee joint tissues ( Figures 8 to 12 Then, the above results are expressed numerically ( Fig.13 ).

[0065] from Fig.13 It was confirmed that the expression levels of IL-1β, PGE2, MMP9, MMP13, and LTB4R in the knee joint tissue of the B. bifidum BGN4-treated group were low.

[0066] IL-1β, IL-6, PGE2, and LTB4R are biomarkers related to inflammation, and MMP9 and MMP13 are biomarkers related to promoting cartilage destruction. Therefore, the reduction of IL-1β, IL-6, PGE2, LTB4R, MMP9, and MMP13 indicates that B. bifidum BGN4 has excellent efficacy in improving, preventing, and treating osteoarthritis.

Claims

1. A food composition for improving osteoarthritis, characterized in that: The invention comprises Bifidobacterium bifidum BGN4 with the deposit number KCCM12754P, a culture solution thereof or a dry powder of the culture solution thereof.

2. The food composition for improving osteoarthritis according to claim 1, characterized in that The food composition is any one selected from lactic acid bacteria fermented milk, soy milk, milk powder, yogurt, beverage, granules or health supplement food.

3. A pharmaceutical composition for preventing or treating osteoarthritis, characterized in that: The invention comprises Bifidobacterium bifidum BGN4 with the deposit number KCCM12754P, a culture solution thereof or a dry powder of the culture solution thereof.